These data indicate that NRF2 is frequently constitutively activated by alternative mechanisms in this cancer type and, therefore, that genetic analyses alone cannot determine the contribution of NRF2 to the tumour phenotype. This evidence concerns the gene NFE2L2 and neoplasm.